![[iStock/FredFroese]](https://www.genengnews.com/wp-content/uploads/2018/08/ObesityDementia_iStock_000036766980Small1555614569-2-218x150.jpg "Molecule Involved in Fasting Adaptations Could Unlock Anti-Obesity Strategies")
In a wide-ranging conversation, CEO John Evans discussed Beam’s pipeline and other preclinical programs. He described the improved safety profile of genome editing therapies, and talked about Beam’s multi-faceted approach when it comes to finding the right delivery vehicle. Evans also talked about Beam’s relationship with Prime Medicine, another David Liu-founded entity, which announced its launch shortly after this interview was recorded with a series A/B round of $315 million . . .
